Pancreatic Cancer Research

ResearcherMashhad University of Medical SciencesNo recent work listed

Mina Maftouh

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5088500012. Sources: OpenAlex.

Their work

Papers
12
Trials
0
Grants
0
Labs led
0
Collaborators
31
Papers, trials and grants by year

2013: 1 paper · 2014: 5 papers · 2015: 1 paper · 2016: 1 paper · 2017: 4 papers

Papers 12

  1. Therapeutic Potential of Curcumin in Treatment of Pancreatic Cancer: Current Status and Future Perspectives. Co-author DOI 10.1002/jcb.25897↗
  2. Targeting stroma in pancreatic cancer: Promises and failures of targeted therapies. Co-author DOI 10.1002/jcp.25798↗
  3. Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer. Co-author DOI 10.1186/s13045-016-0371-1↗
  4. Targeting the Akt/PI3K Signaling Pathway as a Potential Therapeutic Strategy for the Treatment of Pancreatic Cancer. Co-author DOI 10.2174/0929867324666170206142658↗
  5. Circulating microRNAs as Potential Diagnostic, Prognostic and Therapeutic Targets in Pancreatic Cancer. Co-author DOI 10.2174/1381612822666160817095047↗
  6. Pharmacogenomic modeling in pancreatic cancer—letter. Co-author DOI 10.1158/1078-0432.ccr-14-2951↗
  7. Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia. Co-author DOI 10.1038/bjc.2013.681↗
  8. miR-211 modulates gemcitabine activity through downregulation of ribonucleotide reductase and inhibits the invasive behavior of pancreatic cancer cells. Co-author DOI 10.1080/15257770.2014.891741↗
  9. AKT1 and SELP polymorphisms predict the risk of developing cachexia in pancreatic cancer patients. Co-author DOI 10.1371/journal.pone.0108057↗
  10. Galectin-4 expression is associated with reduced lymph node metastasis and modulation of Wnt/β-catenin signalling in pancreatic adenocarcinoma. Co-author DOI 10.18632/oncotarget.2104↗
  11. A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients. Co-author DOI 10.2217/pgs.13.225↗
  12. Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer. Co-author DOI 10.2174/138161213804547312↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Amir Avan · 5 shared papers, 2015–2017 · strength 0.35
  2. Niccola Funel · 7 shared papers, 2013–2017 · strength 0.29
  3. Godefridus J. Peters · 7 shared papers, 2013–2017 · strength 0.29
  4. Elisa Giovannetti · 7 shared papers, 2013–2017 · strength 0.29
  5. Amir Avan · 6 shared papers, 2013–2017 · strength 0.26
  6. Majid Ghayour‐Mobarhan · 4 shared papers, 2014–2017 · strength 0.25
  7. Mina Hosseini · 3 shared papers, 2016–2017 · strength 0.21
  8. Ugo Boggi · 4 shared papers, 2014–2017 · strength 0.17
  9. Majid Khazaei · 2 shared papers, 2017 · strength 0.15
  10. Abolfazl Avan · 3 shared papers, 2014–2015 · strength 0.14
  11. Safieh Ebrahimi · 2 shared papers, 2016–2017 · strength 0.13
  12. Afsane Bahrami · 1 shared paper, 2017 · strength 0.08
  13. Adam Enver Frampton · 2 shared papers, 2013–2014 · strength 0.08
  14. Gordon A. Ferns · 1 shared paper, 2017 · strength 0.07
  15. Andrea Mambrini · 2 shared papers, 2014 · strength 0.07
  16. Maurizio Cantore · 2 shared papers, 2014 · strength 0.07
  17. Sharareh Gholamin · 1 shared paper, 2015 · strength 0.06
  18. Daniela Massihnia · 1 shared paper, 2017 · strength 0.06
  19. Antonio Dello Russo · 1 shared paper, 2017 · strength 0.06
  20. Ana I. Belo · 1 shared paper, 2014 · strength 0.05
  21. Irma van Die · 1 shared paper, 2014 · strength 0.05
  22. Leandro Castellano · 1 shared paper, 2014 · strength 0.04
  23. Tessa Y. S. Le Large · 1 shared paper, 2014 · strength 0.04
  24. Rocco Sciarrillo · 1 shared paper, 2014 · strength 0.04
  25. Karl Quint · 1 shared paper, 2013 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.